Ro5-3335
| Code | Size | Price |
|---|
| TAR-T4687-5mg | 5mg | £148.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T4687-10mg | 10mg | £197.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T4687-25mg | 25mg | £327.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T4687-50mg | 50mg | £518.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T4687-100mg | 100mg | £592.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Ro 5-3335 is core binding factor (CBF) inhibitor; preferentially kills human leukemia cell lines with CBF fusion proteins (IC50 = 1.1 μM). It represses RUNX1/CBFβ-dependent transactivation in reporter assays and inhibits transcriptional regulation by RUNX1 and CBFβ. It also reduces the leukemia burden in a mouse model. Attenuates RUNX1-dependent hematopoiesis in zebrafish embryos. It also is a Tat antagonist and inhibits HIV-1 replication in vitro.
CAS:
30195-30-3
Formula:
C13H10ClN3O
Molecular Weight:
259.69
Pathway:
Cell Cycle/Checkpoint; DNA Damage/DNA Repair
Purity:
0.9995
SMILES:
Clc1ccc2NC(=O)CN=C(c3ccc[nH]3)c2c1
Target:
DNA/RNA Synthesis
References
Wu Y, Hu S S, Zhang R, et al.Single cell RNA sequencing unravels mechanisms underlying senescence-like phenotypes of Alveolar Macrophages.iScience.2023
Okuda T,RUNX1/AML1: a central player in hematopoiesis.Int J Hematol. 2001 Oct;74(3):252-7.
Lin W, Wan X, Sun A, et al. RUNX1/EGFR Pathway Contributes to STAT3 Activation and Tumor Growth Caused by Hyperactivated mTORC1. Molecular Therapy-Oncolytics. 2021
Wang Y, Wang Q, Wang B, et al. Inhibition of EZH2 ameliorates bacteria-induced liver injury by repressing RUNX1 in dendritic cells[J]. Cell death & disease. 2020, 11(11): 1-13.
Wang Y, Wang Q, Wang B, et al. Inhibition of EZH2 ameliorates bacteria-induced liver injury by repressing RUNX1 in dendritic cells. Cell death & disease. 2020, 11(11): 1-13.
Cunningham L, et al.Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBF? interaction.Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14592-7.
Cupelli LA, Hsu MC.The human immunodeficiency virus type 1 Tat antagonist, Ro 5-3335, predominantly inhibits transcription initiation from the viral promoter.J Virol. 1995 Apr;69(4):2640-3.